GlassScriptPhysician profile
James David Diethelm
NPI 1093710410
$5,266.36
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $1,098 · 2021: $1,220 · 2022: $1,221 · 2023: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.46 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $667.44 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.29 | 2019-2023 | Jardiance |
| Abbvie INC. | $457.19 | 2021-2023 | Vraylar |
| Amarin Pharma, INC. | $273.24 | 2019-2021 | |
| Astellas Pharma US INC | $273.01 | 2019-2022 | |
| Pfizer INC. | $244.37 | 2019-2023 | |
| Amgen INC. | $209.62 | 2019-2023 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $198.25 | 2019-2022 | |
| Allergan, INC. | $179.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $169.24 | 2019-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $121.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.38 | 2019-2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $104.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $96.92 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Diethelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.